Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$596.92 USD
+3.13 (0.53%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $596.52 -0.40 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$596.92 USD
+3.13 (0.53%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $596.52 -0.40 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Zacks News
Patterson Companies (PDCO) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Patterson Companies' (PDCO) Q2 results benefit from higher revenues, gross margin expansion and solid show by Dental segment.
What's in the Cards for Cantel Medical (CMD) in Q1 Earnings?
by Zacks Equity Research
Better-than-expected performance at both Medical and Dental segments is likely to have driven Cantel Medical (CMD) in Q1 earnings.
Here's Why You Should Hold on to HealthEquity (HQY) for Now
by Zacks Equity Research
Buoyed by a solid fiscal third quarter, HealthEquity (HQY) raises its fiscal 2020 view.
HealthEquity (HQY) Earnings & Revenues Beat Estimates in Q3
by Zacks Equity Research
Buoyed by a solid fiscal third quarter, HealthEquity (HQY) raises its fiscal 2020 view.
Thermo Fisher Rides on New Product Suite and Global Growth
by Urmimala Biswas
A series of product launches with better precision medicine initiatives aids Thermo Fisher's (TMO) performance.
The Zacks Analyst Blog Highlights: Procter & Gamble, Thermo Fisher, PayPal, NextEra Energy and Enterprise Products
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Procter & Gamble, Thermo Fisher, PayPal, NextEra Energy and Enterprise Products
Cooper Companies (COO) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Better-than-expected performance at CVI and CSI, and higher revenues are likely to have aided Cooper Companies (COO) in Q4 earnings.
Top Analyst Reports for Procter & Gamble, Thermo Fisher & PayPal
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble (PG), Thermo Fisher (TMO) and PayPal (PYPL).
Veeva Systems (VEEV) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Veeva (VEEV) gains from solid segmental contributions in fiscal third quarter, raises fiscal 2020 view.
Here's Why You Should Buy Thermo Fisher (TMO) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about Thermo Fisher (TMO) on its stellar performance.
Here's Why You Should Hold on to Pacific Biosciences Stock
by Zacks Equity Research
Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, stiff competition remains a woe.
Thermo Fisher (TMO) Up 4.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
What's in the Cards for Veeva Systems (VEEV) in Q3 Earnings?
by Zacks Equity Research
Robust product portfolio and higher revenues are likely to have benefited Veeva Systems (VEEV) in third-quarter fiscal 2020 earnings.
Pacific Biosciences (PACB) Q3 Loss Wider Than Estimates
by Zacks Equity Research
Pacific Biosciences (PACB) gains from solid segmental contributions in the third quarter.
Medtronic (MDT) Beats on Q2 Earnings, Ups FY20 EPS Guidance
by Zacks Equity Research
Medtronic (MDT) demonstrates improved performances at CER, banking on growth in all major business segments and geographies.
Canopy Growth (CGC) Q2 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Canopy Growth (CGC) reports mixed fiscal second-quarter results on strength in its core segments.
The Zacks Analyst Blog Highlights: AMETEK, Thermo Fisher Scientific, IQVIA, Lowe's Companies and Alexion Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AMETEK, Thermo Fisher Scientific, IQVIA, Lowe's Companies and Alexion Pharmaceuticals
5 Most-Loved S&P 500 Stocks on Wall Street
by Sweta Killa
Given the bullishness and record-high market, we have screened for five S&P 500 stocks that are most loved by the brokerage firms.
Penumbra's (PEN) Q3 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Penumbra (PEN) witnessed strong growth across all geographies and product lines in Q3.
Dentsply (XRAY) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Dentsply (XRAY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
DexCom (DXCM) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Nevro (NVRO) Q3 Loss Narrower Than Expected, Revenues Up Y/Y
by Zacks Equity Research
Nevro (NVRO) launches the Senza Omnia SCS System commercially in the United States in Q3.
DexCom (DXCM) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
DexCom's (DXCM) Q3 earnings benefit from higher revenues, solid performing Sensor and Transmitter segments and strong 2019 outlook. However, contraction in gross margin remains a woe.
Glaukos (GKOS) Q3 Loss Narrower Than Expected, '19 View Up
by Zacks Equity Research
Glaukos' (GKOS) Q3 revenues surge year over year. Also, the company raises 2019 revenue guidance.
LHC Group (LHCG) Q3 Earnings Surpass Estimates, Revenues Lag
by Zacks Equity Research
LHC Group (LHCG) third-quarter results benefit from home health and hospice admissions and higher revenues.